CAS No. |
83-49-8 |
英文名称 |
(4R)-4-((3R,6S,8S,9S,10R,13R,14S,17R)-3,6-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid |
别名 |
7-deoxyhyocholicacid;alpha-hyodeoxycholicacid;3α,6α-Dihydroxy-5β-cholanoic acid;Hyodeoxycholic;3à,6à-dihydroxy-5á-cholan-24-oic acid;3a,6a-Dihydroxy-5b-Cholan-24-Oic Acid;HYODEOXYCHOLIC ACID FREE ACID;HYODEOXYCHOLIC ACID 98% |
标准英文名 |
(4R)-4-((3R,6S,8S,9S,10R,13R,14S,17R)-3,6-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid |
分子式 |
C24H40O4 |
分子量 |
392.58
|
精确分子量 |
392.29
|
SMILES |
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)C4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |
标准SMILES |
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)C4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C |
用途 |
Hyodeoxycholic acid (HDCA) is used for its hypolipidemic, antispasmodic, and expectorant effects. It is clinically applied in the treatment of hyperlipidemia (types Ia and Ib), atherosclerosis, bronchitis, pediatric viral upper respiratory tract infections, and digestive disorders caused by hepatobiliary diseases. It also exhibits antibacterial activity against Bordetella pertussis, Corynebacterium diphtheriae, and Staphylococcus aureus. As an active ingredient in Qingkailing injection, HDCA has shown efficacy in the treatment of acute leukemia, with in vitro studies demonstrating its ability to induce apoptosis and inhibit cell proliferation. Additionally, it is used in the management of cholangitis, cholecystitis, cholelithiasis, and other non-obstructive cholestasis conditions, and can accelerate the hepatic clearance of cholecystographic agents to enhance imaging. HDCA promotes intestinal fat digestion and absorption of fat-soluble vitamins, and is employed as an anti-inflammatory agent for chronic bronchitis and pediatric viral respiratory infections. |
InChIKey |
DGABKXLVXPYZII-CDONHWFASA-N |